Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-04-18 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
变更部分募集资金用途的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the change in the use of previously raised funds from a stock issuance. It includes specifics about the original fundraising, the amounts raised, the intended and adjusted uses of the funds, agreements with third parties, and approvals from the board and independent directors. The document does not contain financial statements or comprehensive financial performance data but focuses on the update and reallocation of capital raised. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 7,000 characters, indicating it is not a brief announcement but a substantive update on capital use. Therefore, the appropriate classification is CAP with high confidence.
2023-04-18 Chinese
独立董事关于第四届董事会第十七次会议审议事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an announcement from independent directors expressing their opinions on proposals related to changes in the use of previously raised funds. It references compliance with company law, securities law, and stock exchange listing rules. The document is short (949 characters) and serves as an official announcement of independent directors' opinions on board meeting resolutions, not a full report or financial statement. It does not contain financial data or detailed financial results. This fits best under Regulatory Filings (RNS), as it is a regulatory announcement related to board meeting matters and fund usage changes but not a full capital/financing update or management report.
2023-04-18 Chinese
关于全资子公司完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a business registration change for a wholly-owned subsidiary of the company. It details the increase in registered capital of the subsidiary and the completion of the registration process with the local market supervision bureau. The document is short (1021 characters) and primarily serves as a formal notification of a corporate event related to capital increase and registration update. It does not contain financial statements, detailed financial performance, or management discussion. It is not a full report but an announcement of a corporate action. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-04-17 Chinese
关于延长公司股东股份锁定期的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the extension of the lock-up period for shareholders' shares following the company's public stock issuance and listing on the Beijing Stock Exchange. It details commitments by controlling shareholders, actual controllers, and senior management about restrictions on share transfers and lock-up extensions triggered by stock price conditions. The document is a formal disclosure about share lock-up commitments and their extension, not a financial report, earnings release, or management discussion. It is also not a voting result or a capital change announcement. This fits the category of Regulatory Filings (RNS) as it is a regulatory disclosure about share lock-up commitments and extensions related to the company's stock issuance and listing.
2023-04-12 Chinese
2023年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2023 fourth extraordinary shareholders meeting of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder meeting decisions, specifically about changes in the use of raised funds and capital injection into a subsidiary. There is no financial statement or detailed financial analysis presented, nor is this a presentation or transcript. The document is a formal announcement of voting results from a shareholders meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1926 characters), and it contains detailed voting results and legal confirmation, consistent with a DVA filing rather than a report publication or regulatory filing. Therefore, the correct classification is DVA with high confidence.
2023-04-11 Chinese
北京观韬中茂律师事务所关于北京康乐卫士生物技术股份有限公司2023年第四次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedural compliance of the convening and conduct of the 2023 fourth extraordinary general meeting (临时股东大会) of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the convening procedures, qualifications of attendees, voting procedures, and results of the shareholder meeting. It does not contain financial statements or financial performance data. It is not an announcement of voting results but a legal opinion on the meeting's legality. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal opinion document related to corporate governance and shareholder meetings but does not fit into other specific categories such as Declaration of Voting Results (DVA) or Board/Management Information (MANG). The document length is 3532 characters, which is relatively short and focused on legal opinion rather than a full report or announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-04-11 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.